Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Q2 revenue rose 30% to $1.7 billion and GAAP EPS increased 144% to $2.05. Recent FDA approval of a TEVIMBRA-based regimen and positive Phase 3 MANGROVE results provide fresh catalysts; shares were up 15.7% through August 27.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Margin Expansion ⢠Dilution Risk ONC has strong liquidity, improving margins and cash flow, but its high valuation, negative retained earnings, and dilution risk warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Fading Momentum ⢠Critical Support ⢠Overhead Resistance Support Level: $358â359; stronger at $347â348 Resistance Level: $366â369; major at $372â376 ONC remains broadly higher over the last month but is weakening near $358â359 support; hold/reclaim $366â369 for improvement, while a break risks $347â348.
Sentiment & News
Key News Insights: ⢠FDA approval ⢠Positive trial ⢠Access expansion BeOne's FDA approval, positive Phase 3 data, expanded access, and strategic partnerships strengthen its oncology growth outlook.
AI Summary
BeOne's TEVIMBRA/ZIIHERA approval transforms ONC into a broader oncology platform with a credible second growth franchise, but at ~47x forward earnings investors should wait for evidence of rapid commercial uptake and sustained margin expansion before adding aggressively.
Description
BeOne Medicines, formerly BeiGene, is a global oncology company that discovers, develops and commercializes cancer therapies. Headquartered in Cambridge, Massachusetts and redomiciled to Basel in 2025, the firm operates in over 45 countries and maintains a pipeline across hematologic malignancies and solid tumors sourced from internal R&D and external collaborations. Its marketed medicines include the PD-1 antibody Tevimbra (tislelizumab) and the BTK inhibitor Brukinsa (zanubrutinib), the latter generating more than $1.3 billion in annual sales and approved in major markets.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 27 | Sep 3 | ONC | BeOne Medicines Ltd. | Q2 revenue rose 30% to $1.7 billion and GAAP EPS increased 144% to $2.05. Recent FDA approval of a TEVIMBRA-based regimen and positive Phase 3 MANGROVE results provide fresh catalysts; shares were up 15.7% through August 27. | Closed | -2.6% |